Targeting peptide embryo transplantation liquid based on chondroitin sulfate-hyaluronic acid as well as preparation method and application of targeting peptide embryo transplantation liquid

By using chondroitin sulfate-hyaluronic acid targeted peptide embryo transfer fluid, the problems of poor embryo positioning and adhesion during uterine implantation have been solved, improving implantation and pregnancy rates. The composition and preparation process of the transfer fluid have been optimized, reducing costs.

CN121046301APending Publication Date: 2025-12-02JIANGSU MEDNOVO MEDICAL GRP CO LTD
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202511216669.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2025-08-28
Publication Date
2025-12-02

AI Technical Summary

Technical Problem

Existing embryo transfer fluids are not effective in promoting precise embryo positioning and enhancing adhesion, making it difficult to improve implantation rates. Furthermore, they are complex in composition, costly, and the interaction mechanisms between the components are unclear.

Method used

The chondroitin sulfate-hyaluronic acid targeted peptide embryo transfer medium contains chondroitin sulfate, hyaluronic acid, and integrin αVβ3 targeted peptide. By specifically binding to osteopontin, the composition and physicochemical properties of the basic culture medium are optimized. The pH and osmotic pressure are strictly controlled during the preparation process to ensure sterility and stability.

Benefits of technology

It improves the localization and adhesion of the embryo to the endometrium, prolongs the time the embryo stays in the uterus, increases the implantation rate and pregnancy rate, and provides a more efficient success rate for assisted reproduction.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN121046301A_ABST
    Figure CN121046301A_ABST
Patent Text Reader

Abstract

The invention relates to a targeting peptide embryo transplantation liquid based on chondroitin sulfate-hyaluronic acid as well as a preparation method and application thereof, and belongs to the technical field of assisted reproduction. The invention aims to solve the technical problem that pregnancy cannot be obtained due to repeated failure of implantation caused by the fact that an embryo and the surface of an endometrium cannot be accurately positioned and the adhesiveness is poor in the implantation process of the embryo in a uterine cavity. According to the technical scheme, the embryo transplantation liquid comprises a basic culture solution and core components (chondroitin sulfate, hyaluronic acid and integrin alpha V beta 3 targeting peptide), the embryo implantation rate is increased through the synergistic effect of all the components, and meanwhile the preparation method and application of the embryo transplantation liquid are provided.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention belongs to the field of assisted reproductive technology, and specifically provides a targeted peptide embryo transfer fluid based on chondroitin sulfate-hyaluronic acid, its preparation method, and its application. Background Technology

[0002] For understanding the technical content of this invention: In the field of assisted reproductive technology, embryo transfer is a crucial step in achieving pregnancy, and the performance of the embryo transfer fluid plays a decisive role in the embryo implantation rate. Currently, although various embryo transfer fluids are used in clinical practice, many problems remain, making it difficult to effectively improve the embryo implantation rate.

[0003] Most commercially available embryo transfer solutions focus only on providing basic nutrition and maintaining osmotic balance for the embryo, lacking effective mechanisms for regulating the interaction between the embryo and the uterine lining. While some solutions add components to improve the embryo's environment, their effectiveness in promoting precise embryo placement and enhancing adhesion is limited, making stable implantation difficult and a significant factor restricting the success rate of assisted reproductive technology. Furthermore, current research on optimizing the concentration and combination of components in embryo transfer solutions is insufficient, failing to fully leverage their synergistic effects and resulting in persistently low implantation rates that fail to meet clinical needs.

[0004] Relevant patent documents retrieved: The document, published in China (CN111944742A) on July 18, 2023, discloses an embryo transfer fluid composed of acetylsalicylic acid, heparin, polyvinylpyrrolidone, aromatase inhibitors, various growth factors, and other components, along with a basal culture medium. It aims to improve the uterine environment, thereby increasing embryo implantation rate, pregnancy rate, and birth rate. The basal culture medium contains inorganic salts and amino acids.

[0005] Relevant non-patent literature retrieved: The journal title is *Reproduction, Fertility and Development*, and the article title is "Effect of glycosaminoglycans on the preimplantation development of embryos derived from in vitro fertilization and somatic cell nuclear transfer," volume 15, published in 2003. This article discloses that adding glycosaminoglycans (GAGs) such as hyaluronic acid, heparin, or chondroitin sulfate to a modified synthetic oviduct fluid (mSOF) can improve the blastocyst formation rate of bovine in vitro fertilization (IVF) and somatic cell nuclear transfer (SCNT) embryos. Furthermore, a concentration of 0.5 mg / mL of GAGs can increase the total number of cells and the number of trophectoderm cells in SCNT blastocysts. This only demonstrates a promoting effect on blastocyst formation and lacks clear data to support an improvement in implantation rate.

[0006] Multiple studies, including "Routine use of EmbryoGlue® as embryo transfer medium does not improve the ART outcomes," "Evaluation of a transfer medium containing high concentration of hyaluronan in human in vitro fertilization," and "Hyaluronic acid can successfully replace albumin as the sole macromolecule in a human embryo transfer medium," have indicated that adding HA only slightly improves or does not significantly increase implantation and pregnancy rates. This may be related to insufficient interaction between HA and the embryo and the endometrial surface.

[0007] The prior art represented by the aforementioned documents has at least the following unresolved technical problems or defects: The embryo transfer fluid in existing technologies has a complex composition and high cost. The interaction mechanism between the components is unclear. Relevant evidence includes: CN111944742B uses 44 components in its examples, and many non-patent literature searches have only explored the effects of a single component. Summary of the Invention

[0008] The purpose of this invention is to provide: A targeted peptide embryo transfer solution based on chondroitin sulfate-hyaluronic acid, its preparation method and application, and related technologies, to solve technical problems such as the inability to accurately position the embryo on the endometrial surface during uterine implantation and poor adhesion leading to repeated implantation failures, or a combination thereof.

[0009] Terminology Explanation: Unless otherwise defined, all technical terms in this document have the same meanings as commonly understood by one of ordinary skill in the art to which the subject matter of the claims pertains. Unless otherwise stated, all patents, patent inventions, and publications cited in this document are incorporated herein by reference in their entirety. If multiple definitions exist for terms in this document, the definitions in this chapter shall prevail.

[0010] It should be understood that the above brief description and the following detailed description are exemplary and for illustrative purposes only, and do not limit the subject matter of the invention in any way. In this invention, the singular is used in conjunction with the plural unless otherwise specifically stated. It should also be noted that, unless otherwise stated, the use of “or” or “or” means “and / or”. Furthermore, the use of the term “comprising” and other forms such as “including,” “containing,” and “contains” are not limiting.

[0011] The definition of standard chemical terms can be found in the reference "Reproductive Medicine Center System and Assisted Reproductive Technology", Fu Lei et al., Science and Technology Literature Press.

[0012] Unless otherwise stated, conventional methods within the scope of the art, such as embryo culture techniques, embryo transfer procedures, pH and osmolarity detection methods, etc., shall be used.

[0013] Unless specifically defined herein, the use of all commercially available products herein employs standard techniques. For example, it may be carried out using the manufacturer's instructions for use with the kit, or in accordance with methods known in the art or the description of this invention. The techniques and methods described herein can generally be implemented according to conventional methods well known in the art, based on the descriptions in the various summary and more specific documents cited and discussed in this specification.

[0014] The terms "optional / arbitrary" or "optionally / arbitrarily" refer to events or situations described subsequently that may or may not occur, including both the occurrence and non-occurrence of the event or situation. For example, according to the definition below: "optionally added antibiotics" means "adding antibiotics" or "not adding antibiotics".

[0015] The term "chondroitin sulfate (CS)" used in this article refers to a class of high molecular weight acidic mucopolysaccharides that are mainly distributed in the cartilage and bones of mammals. It can interact with many proteins, participate in the regulation of various biological and pathological processes, and has good tissue compatibility.

[0016] The term “hyaluronic acid (HA)” used in this article refers to a non-sulfated glycosaminoglycan macromolecule composed of N-acetyl-D-glucosamine and D-glucuronic acid linked alternately by β-(1→4) and β-(1→3) glycosidic bonds. It is one of the main components of the extracellular matrix and has good lubricity and high viscosity.

[0017] The term "integrin αVβ3 targeting peptide" as used in this article refers to a peptide containing an RGD binding sequence that can specifically bind osteopontin (OPN), with the preferred amino acid sequence being KGGGCRGDMFGCA.

[0018] The term "basal culture medium" as used in this article refers to a liquid culture medium containing inorganic salts, buffers, energy components, antibiotics, and proteins, which provides a basic living environment for the embryo.

[0019] In a first aspect, the present invention provides: a targeted peptide embryo transfer solution based on chondroitin sulfate-hyaluronic acid.

[0020] This includes technical features: core components, basic culture medium, and physicochemical properties.

[0021] Among them, the technical features “core components” include chondroitin sulfate 0.1-2.0 g / L, hyaluronic acid 0.1-2.0 g / L and integrin αVβ3 targeting peptide 0.01-0.1 mM.

[0022] Hyaluronic acid includes hyaluronic acid salts and their analogues, wherein the hyaluronic acid salts include, but are not limited to, at least one of sodium hyaluronate, potassium hyaluronate, magnesium hyaluronate, calcium hyaluronate, or zinc hyaluronate.

[0023] The preferred hyaluronic acid salt is sodium hyaluronate.

[0024] Preferably, the core components of the targeted embryo transfer fluid include chondroitin sulfate 0.1-2.0 g / L, hyaluronic acid 0.1-2.0 g / L, and integrin αVβ3 targeting peptide 0.01-0.1 mM.

[0025] In certain specific embodiments of the present invention, the core components of the targeted embryo transfer fluid include chondroitin sulfate 1.0 g / L, sodium hyaluronate 1.0 g / L, and integrin αVβ3 targeting peptide 0.05 mM.

[0026] Among them, the technical feature "integrin αVβ3 targeting peptide" contains an RGD binding sequence for specifically binding osteopontin (OPN).

[0027] The preferred integrin αVβ3 targeting peptide is the sequence shown in SEQ ID NO.1.

[0028] SEQ ID NO. 1: KGGGCRGDMFGCA.

[0029] The technical feature "basal culture medium" includes inorganic salts, buffers, energy components, antibiotics, and human serum albumin.

[0030] The preferred basic culture medium is: sodium chloride 70-140mM, potassium chloride 3-7mM, magnesium sulfate 0.1-0.3mM, potassium dihydrogen phosphate 0.2-0.6mM, calcium chloride 1.4-3.0mM, sodium bicarbonate 15-35mM, sodium lactate 14-28mM, anhydrous glucose 1.9-4.0mM, sodium pyruvate 0.2-0.5mM, human serum albumin 2.5-7.5g / L, and gentamicin sulfate 0.005-0.0100g / L.

[0031] The basal culture medium is further preferably composed of: sodium chloride 101.6 mM, potassium chloride 4.69 mM, magnesium sulfate 0.2 mM, potassium dihydrogen phosphate 0.37 mM, calcium chloride 2.04 mM, sodium bicarbonate 25 mM, sodium lactate 21.4 mM, glucose 2.78 mM, sodium pyruvate 0.33 mM, human serum albumin 5 g / L, and gentamicin sulfate 10 mg / L.

[0032] Among them, the technical characteristic "physicochemical properties" meets the requirements of the Chinese Pharmacopoeia or foreign pharmacopoeias; Among them, the preferred physicochemical properties meet the requirements of the current version of the Chinese Pharmacopoeia; The preferred physicochemical properties are: pH 7.0-7.6 at 20-30℃; osmotic pressure 255-295 mOsm / kg.

[0033] Based on further solutions to the technical problems of the present invention, or simultaneous solutions to multiple technical problems, the preferred solution in the technical solution provided in the first aspect of the present invention includes: The first preferred protocol: The basal culture medium consists of sodium chloride 70-140 mM, potassium chloride 3-7 mM, magnesium sulfate 0.1-0.3 mM, potassium dihydrogen phosphate 0.2-0.6 mM, calcium chloride 1.4-3.0 mM, sodium bicarbonate 15-35 mM, sodium lactate 14-28 mM, anhydrous glucose 1.9-4.0 mM, sodium pyruvate 0.2-0.5 mM, human serum albumin 2.5-7.5 g / L, and gentamicin sulfate 0.005-0.0100 g / L. The core components are chondroitin sulfate 0.1-2.0 g / L, sodium hyaluronate 0.1-2.0 g / L, and integrin αVβ3 targeting peptide 0.01-0.1 mM (sequence KGGGCRGDMFGCA). The pH is 7.30 at 25℃±2℃, and the osmotic pressure is 275 mOsm / kg. This technical solution not only addresses the issues of poor embryo positioning and adhesion to the endometrial surface, but also further optimizes the stability and applicability of the transfer solution.

[0034] Secondly, the preparation method of the above-mentioned chondroitin sulfate-hyaluronic acid-based targeted peptide embryo transfer solution includes the following steps: S1: Dissolve the components of the basic culture medium in a solvent; S2: Add chondroitin sulfate and sodium hyaluronate, and stir to dissolve; S3: Aseptically filtered through a 0.22μm filter membrane; S4: Add integrin αVβ3 targeting peptide before use and mix well.

[0035] This includes technical features such as solvent selection, preparation of basic culture medium, addition of some core components, and addition and balancing of targeted peptides.

[0036] The solvent is selected from: purified water, water for injection, and sterile water for injection.

[0037] The preferred solvent is water for injection.

[0038] The basic culture medium is prepared by dissolving inorganic salts, buffers, energy components, antibiotics, and proteins in a solvent in a certain proportion and stirring until dissolved.

[0039] The preferred method for preparing the basic culture medium is as follows: preheat the solvent to 25°C, and dissolve sodium chloride, potassium chloride, magnesium sulfate, potassium dihydrogen phosphate, calcium chloride, sodium bicarbonate, sodium lactate, anhydrous glucose, and sodium pyruvate in sequence. Add human serum albumin and gentamicin sulfate, and stir until completely dissolved.

[0040] Some of the core components are selected from: adding chondroitin sulfate and sodium hyaluronate, stirring to dissolve, and then aseptically filtering through a 0.22μm filter membrane.

[0041] The preferred method for adding some core components is as follows: add chondroitin sulfate and sodium hyaluronate, stir at 200-300 rpm for 30 minutes until transparent and free of particles, filter through a 0.22 μm microporous membrane for sterilization, and dispense into sterile containers.

[0042] The addition and balancing of the target peptide are selected as follows: before use, add integrin αVβ3 target peptide, mix well and warm to 37°C. The transplantation solution needs to be gas balanced before addition.

[0043] The preferred method for adding and balancing the targeting peptide is as follows: equilibrate in a 5% CO2, 37°C incubator for 30 min, adjust the pH to 7.2-7.4, add the integrin αVβ3 targeting peptide, mix gently, and warm to 37°C for later use.

[0044] Based on further solutions to the technical problems of the present invention, or simultaneous solutions to multiple technical problems, the preferred solution in the technical solution provided in the second aspect of the present invention includes: The first preferred approach: The solvent is water for injection. The basal culture medium is prepared according to the above components and proportions, the core components are added, and after filtration through a 0.22μm filter membrane, it is equilibrated in a 5% CO2, 37℃ incubator for 30 min. The pH is adjusted to 7.2-7.4, and 0.05mM integrin αVβ3 targeting peptide (sequence KGGGCRGDMFGCA) is added. After mixing and warming to 37℃, the solution addresses the sterility and stability issues in the preparation of the transplantation medium and further improves the activity retention rate of the targeting peptide.

[0045] Thirdly, the present invention provides the application of the above-mentioned chondroitin sulfate-hyaluronic acid-based targeted peptide embryo transfer solution in improving the implantation rate of mammalian embryos.

[0046] This includes technical characteristics: the target audience.

[0047] The target populations are selected from mammals such as humans, mice, and rabbits.

[0048] The preferred subjects for application are: humans, mice, and rabbits.

[0049] Based on further solutions to the technical problems of the present invention, or simultaneous solutions to multiple technical problems, the preferred solution in the technical solution provided in the third aspect of the present invention includes: The first priority option is to apply it to unilateral uterine transfer of mouse blastocysts. This technique not only solves the problem of low embryo implantation rate in mice, but also provides reliable animal experimental evidence for human assisted reproductive applications.

[0050] Embodiments 1-3 of this invention at least support the protection scope of claim 1.

[0051] Regarding the claim 1: The technical feature “basal culture medium (containing inorganic salts, buffers, energy components, antibiotics, and proteins)” is derived from the aforementioned explanation and / or the corresponding basic culture medium components in Examples 1-3, summarized by the common feature “liquid culture medium providing a basic survival environment for the embryo.” Therefore, those skilled in the art can reasonably infer that this technical feature, its subordinate concepts (such as combinations of inorganic salts with different concentration ranges), substantially equivalent technical means (such as replacing gentamicin sulfate with other suitable antibiotics), and technical means that can be replaced within the scope of conventional technical means and common knowledge based on the existing level of technology should all fall within the protection scope of claim 1. For example, replacing gentamicin sulfate with penicillin while keeping other technical features unchanged still falls within the protection scope of claim 1 of this invention.

[0052] The technical feature “chondroitin sulfate (0.1-2.0 g / L)” is derived from the foregoing explanation and / or the corresponding chondroitin sulfate concentrations in Examples 1-3 (1.0 g / L in Example 1, 0.5 g / L in Example 2, and 1.5 g / L in Example 3) summarized by the common feature “acidic mucopolysaccharide, involved in the regulation of cell-related biological processes”. Therefore, those skilled in the art can reasonably infer that this technical feature, its subordinate concepts (such as chondroitin sulfate of different molecular weights), substantially equivalent technical means (such as chondroitin sulfate derivatives), and technical means that can be replaced by conventional technical means and common knowledge based on the existing level of technology should all fall within the protection scope of claim 1. For example, if other technical features remain unchanged, using chondroitin sulfate derivatives with a concentration in the range of 0.1-2.0 g / L still falls within the protection scope of claim 1 of this invention.

[0053] The technical feature “hyaluronic acid (0.1-2.0 g / L, preferably sodium hyaluronate)” is derived from the foregoing explanation and / or the corresponding sodium hyaluronate concentrations in Examples 1-3 (1.0 g / L in Example 1, 0.5 g / L in Example 2, and 1.5 g / L in Example 3) summarized by the common feature “non-sulfated glycosaminoglycans with lubricity and high viscosity”. Therefore, those skilled in the art can reasonably infer that this technical feature, its subordinate concepts (such as sodium hyaluronate of different molecular weights), substantially equivalent technical means (such as other salt forms of hyaluronic acid), and technical means that can be replaced by conventional technical means and common knowledge based on the existing level of technology should all fall within the protection scope of claim 1. For example, if potassium hyaluronate is used with a concentration in the range of 0.1-2.0 g / L while other technical features remain unchanged, it still falls within the protection scope of claim 1 of this invention.

[0054] The technical feature “integrin αVβ3 targeting peptide (0.01-0.1 mM, containing RGD binding sequence)” is derived from the aforementioned explanation and / or the corresponding targeting peptide concentrations and sequences in Examples 1-3 (Example 1: 0.05 mM, sequence KGGGCRGDMFGCA, etc.) through the common feature “specifically binds to osteopontin.” Therefore, those skilled in the art can reasonably infer that this technical feature, its subordinate concepts (such as other peptides containing RGD binding sequences), substantially equivalent technical means (such as structurally similar targeting peptides), and technical means that can be replaced within the scope of conventional and common knowledge based on the existing level of technology should all fall within the protection scope of claim 1. For example, using other peptides containing RGD binding sequences at a concentration in the range of 0.01-0.1 mM while keeping other technical features unchanged still falls within the protection scope of claim 1 of this invention.

[0055] The technical feature "preparation steps (S1-S4)" is summarized from the corresponding preparation operations in the foregoing explanation and / or Examples 1-3 (S1 dissolving the basic culture medium components, S2 adding chondroitin sulfate and sodium hyaluronate, S3 aseptic filtration, S4 adding the targeting peptide) through the common feature "aseptic preparation of a transplant fluid with specific components". Therefore, those skilled in the art can reasonably presume that this technical feature, its subordinate concepts (such as adjusting the stirring speed or dissolution order), substantially equivalent technical means (such as using sterile filter membranes of other specifications), and technical means that can be replaced within the scope of conventional technical means and common knowledge based on the existing level of technology should all fall within the protection scope of claims 10-15. For example, replacing the 0.22μm filter membrane with a 0.2μm filter membrane with the same sterilization effect while keeping other technical features unchanged still falls within the protection scope of claims 10-15 of this invention.

[0056] The technical feature "solvent selection" is derived from the foregoing explanation and / or the use of water for injection as a solvent in Examples 1-3, summarized by the common feature "solvent that meets sterility requirements". Therefore, those skilled in the art can reasonably presume that this technical feature, its subordinate concepts (such as different grades of water for injection), substantially equivalent technical means (such as sterile water for injection), and technical means that can be replaced by conventional technical means and common knowledge based on the existing level of technology should all fall within the protection scope of claims 10-15. For example, replacing water for injection with sterile water for injection while keeping other technical features unchanged still falls within the protection scope of claims 10-15 of this invention.

[0057] The technical feature "gas balance and physicochemical property adjustment" is derived from the gas balance operation and pH and osmotic pressure control described in the foregoing explanation and / or Examples 1-3, summarized by the common feature "maintaining the physiological compatibility of the transplant fluid". Therefore, those skilled in the art can reasonably infer that this technical feature, its subordinate concepts (such as fine-tuning the balance time), substantially equivalent technical means (such as using other gas environments for balance), and technical means that can be replaced by conventional technical means and common knowledge based on the existing level of technology should all fall within the protection scope of claims 10-15. For example, adjusting the balance time from 30 min to 25-35 min while keeping other technical features unchanged still falls within the protection scope of claims 10-15 of this invention.

[0058] Examples 1-3 and Detection Example 2 in this invention at least support the protection scope of claims 16-17. Regarding claims 16-17: The technical feature "application to improve the implantation rate of mammalian embryos" is summarized from the aforementioned explanation and / or the implantation rate data of mouse transplantation experiments in Examples 1-3 and Detection Example 2 (the implantation rate in Examples 1-3 was significantly higher than that in the control group) by the common feature "enhancing the embryo implantation effect through the synergistic effect of transplantation fluid components". Therefore, those skilled in the art can reasonably presume that this technical feature, its subordinate concepts (such as applications to different strains of mice), substantially equivalent technical means (such as adjusting the number of transplanted embryos), and technical means that can be replaced by conventional technical means and common knowledge based on the existing level of technology should all fall within the protection scope of claims 16-17. For example, if the application object is changed from mice to rabbits while other technical features remain unchanged, it still falls within the protection scope of claims 16-17 of this invention.

[0059] The technical feature "mammal application subject" is derived from the foregoing explanation and / or the common feature "covering humans and experimental animals" used in Examples 1-3 and Detection Example 2, which used mice as experimental subjects. Therefore, those skilled in the art can reasonably infer that this technical feature, its subordinate concepts (such as mammals of different ages), substantially equivalent technical means (such as other rodent models), and technical means that can be replaced by conventional technical means and common knowledge based on the existing level of technology should all fall within the protection scope of claims 16-17. For example, if the application subject is changed from ICR mice to BALB / c mice while other technical features remain unchanged, it still falls within the protection scope of claims 16-17 of this invention.

[0060] The present invention has at least the following beneficial effects: The combination of chondroitin sulfate (CS) and hyaluronic acid (HA) in the embryo transfer fluid provided by this invention can provide suitable viscosity, prolong the time the embryo stays in the uterus, and increase the implantation rate when the endometrium reaches the appropriate implantation window and adheres to the endometrium.

[0061] The targeted peptide added to the embryo transfer fluid provided by this invention can bind to osteopontin (OPN), which can enhance the positioning and adhesion of the embryo to the endometrium, thereby improving the pregnancy rate and birth rate. Attached Figure Description

[0062] Figure 1 The image shows 10 gestational sacs after the transplantation fluid prepared in Example 1 of this invention was applied to mice, with the green arrow pointing to the gestational sacs. Detailed Implementation

[0063] The following non-limiting embodiments are intended to enable those skilled in the art to gain a more comprehensive understanding of the present invention, but do not limit the invention in any way. The following content is merely an exemplary description of the scope of protection claimed by the present invention, and those skilled in the art can make various changes and modifications to the present invention based on the disclosed content, and such changes should also fall within the scope of protection claimed by the present invention.

[0064] The present invention will be further described below by way of specific embodiments. Unless otherwise specified, all instruments, devices, equipment, reagents, products, etc., used in the embodiments of the present invention are obtained through conventional commercial means.

[0065] Examples 1-3 and Comparative Examples 1-5 provide a transplantation solution, the specific components and final concentration of which are shown in Table 1.

[0066] Table 1. Transplantation fluids of Examples 1-3 and Comparative Examples 1-5

[0067] The preparation method of the transplantation fluid in this example includes the following steps: 1) Preparation of basic culture medium: Take solvent, preheat to 25°C, and dissolve inorganic salts (sodium chloride, potassium chloride, magnesium sulfate, potassium dihydrogen phosphate, and calcium chloride), buffer (sodium bicarbonate), and energy components (sodium lactate, anhydrous glucose, and sodium pyruvate) in the order of concentrations in Table 1. Add human serum albumin (HSA) and gentamicin sulfate, and stir until completely dissolved.

[0068] 2) Add core components: Add chondroitin sulfate (CS) and sodium hyaluronate (HA), and stir until clear and free of particles (200-300 rpm, 30 min).

[0069] 3) Aseptic treatment: The solution is sterilized by filtration through a 0.22 μm microporous membrane and then dispensed into sterile containers.

[0070] 4) Addition and equilibration of the target peptide: Equilibrate in a 5% CO2, 37℃ incubator for 30 min, adjust the pH to 7.2-7.4, add the integrin αVβ3 target peptide (sequence: KGGGCRGDMFGCA), mix gently, and warm to 37℃ for later use.

[0071] The difference between the preparation methods of Comparative Example 1 and Example 1 is that step 4) of adding and balancing the target peptide is not performed during the preparation of Comparative Example 1.

[0072] The difference between the preparation methods of Comparative Example 2 and Example 1 is that in the preparation of Comparative Example 2, only sodium hyaluronate is added in the core component addition step 2), and chondroitin sulfate is not added.

[0073] The difference between the preparation methods of Comparative Example 3 and Example 1 is that in the preparation of Comparative Example 3, only chondroitin sulfate is added in step 2) of the core component addition step, and sodium hyaluronate is not added.

[0074] The difference between the preparation methods of Comparative Example 4 and Example 1 is that the core component addition step (step 2) is not performed during the preparation of Comparative Example 4.

[0075] The difference between the preparation methods of Comparative Example 5 and Example 1 is that Comparative Example 5 does not perform step 2) the core component addition step, nor does it perform step 4) the addition and balancing of the target peptide.

[0076] Test Example 1: pH and Osmolarity Test The specific operational differences, pH values, and osmotic pressure test results of Examples 1-3 and Comparative Examples 1-5 are shown in Table 2. The pH and osmotic pressure test methods were based on the pH value determination method and the osmotic pressure molar concentration determination method of the 2025 edition of the Pharmacopoeia of the People's Republic of China, respectively.

[0077] Table 2. Specific operational differences and pH and osmotic pressure tests in Examples 1-3 and Comparative Examples 1-5.

[0078] Key control parameters: 1) pH adjustment: After gas equilibrium is achieved, the pH must be strictly controlled between 7.2 and 7.4; 2) Osmotic pressure: The final osmotic pressure range is 255-295 mOsm / kg.

[0079] 3) Aseptic operation: All steps are performed in a laminar flow hood, and the filter membrane undergoes an integrity test before use.

[0080] Example 2: Mouse Experiment To further evaluate the application of embryo transfer fluid in assisted reproductive technology, mouse blastocysts were used for unilateral uterine transfer, and the implantation rate was assessed. The specific procedures are as follows: 1) Blastocyst preparation: Six-week-old female ICR mice were ovulated (PMSG / hCG) and mated with male mice. The day of vaginal plugging was confirmed as day 0.5 of pregnancy. On day 3.5, embryos were flushed, and morphologically normal blastocysts were selected for use.

[0081] 2) Pretreatment of transplantation fluid: Transplantation fluids were prepared according to Examples 1-3 and Comparative Examples 1-5, respectively.

[0082] 3) Gas equilibration: Place in a 5% CO2, 37℃ incubator for 30 min to equilibrate until the pH stabilizes to 7.2-7.4.

[0083] 4) Adding the target peptide: Add the integrin αVβ3 target peptide (KGGGCRGDMFGCA) before use, mix well and keep warm at 37°C.

[0084] 5) Unilateral uterine transplantation: Anesthetize recipient pseudopregnant mice (2.5 days after mating of ligated male mice). Expose the left uterine horn and aspirate 10 blastocysts (transfer fluid volume ≤2 μL) using a transfer needle. Inject into the middle of the uterine cavity and suture the incision.

[0085] 6) Implantation rate assessment: On day 6 post-transfer, the uterus was dissected and the gestational sacs (grossly vascular clusters were visible to the naked eye) were counted. The gestational sacs after application of the transplantation fluid prepared in Example 1 of this invention in mice were as follows: Figure 1 As shown.

[0086] Table 3. Implantation rate data for each group

[0087] Note: 1) n=8 (8 recipient mice per group, 10 blastocysts transplanted per mouse) 2) Significance test: t-test, *p<0.05, **p<0.01 3) Implantation rate calculation formula: (Number of gestational sacs / Number of embryos transferred) × 100% Based on the experimental results in Table 3, the following conclusions can be drawn: 1) Synergistic effect of core components: Example 1 (CS 1.0 g / L + HA 1.0 g / L + targeting peptide 0.05 mM) showed an implantation rate as high as 75%, significantly higher than other groups (p<0.01). The absence of any core component (Comparative Examples 1-4) resulted in a decrease in implantation rate of ≥22%, demonstrating that the adhesion and prolongation effect of CS / HA and the localization function of the targeting peptide are both indispensable.

[0088] 2) The core value of the targeting peptide: The implantation rate of Comparative Example 1 (without targeting peptide) (53%) was significantly lower than that of Example 1 (75%), indicating that the targeting peptide enhances localization and adhesion by binding to OPN, which is the key to improving efficiency.

[0089] Finally, it should be noted that the above content is only used to illustrate the technical solution of the present invention, and is not intended to limit the scope of protection of the present invention. Simple modifications or equivalent substitutions made by those skilled in the art to the technical solution of the present invention do not depart from the essence and scope of the technical solution of the present invention.

Claims

1. A targeted peptide embryo transfer solution based on chondroitin sulfate-hyaluronic acid, comprising core components and a basal culture medium, characterized in that, The core components include chondroitin sulfate 0.1-2.0 g / L, hyaluronic acid 0.1-2.0 g / L, and integrin αVβ3 targeting peptide 0.01-0.1 mM.

2. The targeted embryo transfer solution according to claim 1, characterized in that, The hyaluronic acid is a hyaluronic acid salt or its analogues, including sodium hyaluronate, potassium hyaluronate, magnesium hyaluronate, calcium hyaluronate, or zinc hyaluronate.

3. The targeted embryo transfer solution according to claim 2, characterized in that, The hyaluronic acid salt is sodium hyaluronate.

4. The targeted embryo transfer solution according to claim 3, characterized in that, The core components include: chondroitin sulfate 0.5-1.5 g / L, sodium hyaluronate 0.5-1.5 g / L, and integrin αVβ3 targeting peptide 0.025-0.075 mM.

5. The targeted embryo transfer solution according to claim 4, characterized in that, The core components include: chondroitin sulfate 1.0 g / L, sodium hyaluronate 1.0 g / L, and integrin αVβ3 targeting peptide 0.05 mM.

6. The targeted embryo transfer solution according to claim 1, characterized in that, The integrin αVβ3 targeting peptide contains an RGD binding sequence.

7. The targeted embryo transfer solution according to claim 6, characterized in that, The amino acid sequence of the integrin αVβ3 targeting peptide is shown in SEQ ID NO.

1.

8. The targeted embryo transfer solution according to claim 1, characterized in that, The basic culture medium includes: sodium chloride 70-140mM, potassium chloride 3-7mM, magnesium sulfate 0.1-0.3mM, potassium dihydrogen phosphate 0.2-0.6mM, calcium chloride 1.4-3.0mM, sodium bicarbonate 15-35mM, sodium lactate 14-28mM, anhydrous glucose 1.9-4.0mM, sodium pyruvate 0.2-0.5mM, human serum albumin 2.5-7.5g / L, and gentamicin sulfate 0.005-0.0100g / L.

9. The targeted embryo transfer fluid according to any one of claims 1-8, characterized in that, The pH of the targeted embryo transfer fluid is 7.0-7.6 at 20-30℃; the osmotic pressure is 255-295 mOsm / kg.

10. The method for preparing the targeted embryo transfer fluid according to any one of claims 1-9, characterized in that, Includes the following steps: S1: Dissolve the components of the basic culture medium in a solvent; S2: Add chondroitin sulfate and sodium hyaluronate, and stir to dissolve; S3: Aseptically filtered through a 0.22μm filter membrane; S4: Add integrin αVβ3 targeting peptide before use and mix well.

11. The preparation method according to claim 10, characterized in that, In S1, the solvent is selected from purified water and water for injection.

12. The preparation method according to claim 11, wherein the water for injection is sterile water for injection.

13. The preparation method according to claim 10, characterized in that, In S4, the transplantation fluid needs to be gas-balanced before adding the integrin αVβ3 targeting peptide.

14. The preparation method according to claim 13, characterized in that, The process of achieving gas balance also includes adjusting the targeted embryo transfer fluid.

15. The preparation method according to claim 14, characterized in that, The pH of the targeted embryo transfer fluid is 7.0-7.6 at 20-30℃.

16. The preparation method according to claim 10, characterized in that, The final osmotic pressure of the targeted embryo transfer fluid is adjusted to 255-295 mOsm / kg.

17. The use of the targeted embryo transfer fluid according to any one of claims 1-9 or the targeted embryo transfer fluid prepared by the preparation method according to any one of claims 10-16 in improving the implantation rate of mammalian embryos.

18. The application according to claim 17, characterized in that, The mammals mentioned include: humans, mice, or rabbits.

Citation Information

Patent Citations

  • Embryo transplantation solution

    CN111944742A

  • An embryo transfer fluid

    CN111944742B